Home > Insider Trading > Filing (0001209191-19-053665)

Filing Details

Accession Number:: 0001209191-19-053665
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-10-18 19:56:28
Reporting Period:: 2019-10-16

Accepted Time:: 2019-10-18 19:56:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1706431	Vir Biotechnology Inc.	VIR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1219042	Robert Nelsen	8755 W. Higgins Road, Suite 1025 Chicago IL 60631		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-10-16	11,666,665	$0.00	12,111,109	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-10-16	15,555,554	$0.00	15,555,554	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-10-16	1,000,000	$20.00	1,000,000	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2019-10-16	11,111,110	$0.00	11,111,110	$0.00
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2019-10-16	13,333,332	$0.00	13,333,332	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2019-10-16	555,555	$0.00	555,555	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2019-10-16	2,222,222	$0.00	2,222,222	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of the Issuer's Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX, L.P., which is the sole general partner of ARCH IX, and shares voting and investment control with respect to shares held by ARCH IX. The Reporting Person may be deemed to beneficially own the shares held by ARCH IX, and the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, which is the sole general partner of ARCH Venture Partners IX Overage, L.P., the sole general partner of ARCH Overage, and shares voting and investment control with respect to shares held by ARCH Overage. The Reporting Person may be deemed to beneficially own the shares held by ARCH Overage, and the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These shares are directly held by GPLLC. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by GPLLC. Each of the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Each of ARCH IX and ARCH Overage has a pecuniary interest in the shares held by GPLLC.